Who are Reference(Stillen tab.)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Levoxyl, Euthyrox (levothyroxine), L-Thyroxine (tablet, per os), Thyroid hormone, Levothyroxine-Na + iodide, Levothyroxine Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/reference-stillen-tab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Reference(Stillen tab.) — Competitive Intelligence Brief

Reference(Stillen tab.) (Reference(Stillen tab.)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone replacement. Area: Endocrinology.

phase 3 Thyroid hormone replacement Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Reference(Stillen tab.) (Reference(Stillen tab.)) — Daewon Pharmaceutical Co., Ltd.. Stillen is a medication used to treat hypothyroidism.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Reference(Stillen tab.) TARGET	Reference(Stillen tab.)	Daewon Pharmaceutical Co., Ltd.	phase 3	Thyroid hormone replacement
Levoxyl	Levothyroxine Sodium	Pfizer Inc.	marketed	Thyroid hormone replacement	Thyroid receptor proteins attached to DNA
Euthyrox (levothyroxine)	Euthyrox (levothyroxine)	University Medical Center Groningen	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha and TR-beta)
L-Thyroxine (tablet, per os)	L-Thyroxine (tablet, per os)	Meyer Children's Hospital IRCCS	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha, TR-beta)
Thyroid hormone	Thyroid hormone	Merck Sharp & Dohme LLC	marketed	Thyroid hormone replacement	Thyroid hormone receptors (TR-alpha, TR-beta)
Levothyroxine-Na + iodide	Levothyroxine-Na + iodide	Sanofi	marketed	Thyroid hormone replacement therapy	Thyroid hormone receptors (TR-alpha and TR-beta)
Levothyroxine Tablet	Levothyroxine Tablet	University of California, Los Angeles	marketed	Thyroid hormone replacement	Thyroid hormone receptor (TR-alpha and TR-beta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone replacement class)

Pfizer Inc. · 2 drugs in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
M. Medici · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Meyer Children's Hospital IRCCS · 1 drug in this class
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sanofi · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Reference(Stillen tab.) — Competitive Intelligence Brief. https://druglandscape.com/ci/reference-stillen-tab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab